The combined annual global market size of the indications we are targeting is over US$110 billion, which is derived from the total addressable market for the treatment of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and GAD. Success in the clinical development programmes will not only provide benefit to patients suffering from untreated medical conditions, but also significant economic potential for shareholders.
IHL – 42X – OSA IHL-42X is a novel cannabinoid combination product for treatment of Obstructive Sleep Apnoea (OSA).
US$110 billion potential.
Stay up to date with Incannex’s research and development program.